Leaflet SERROFLO 25mcg / 125mcg / dose pressurized inhalation suspension


Indicated for: asthma; chronic obstructive pulmonary disease

Route of administration: inhalation

Substance: salmeterol + fluticasone (beta-2 adrenergic agonist + glucocorticoid)

ATC: R03AK06 (Respiratory system | Adrenergics, inhalants | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics)

Precautions:
Glaucoma warning
Glaucoma warning

Use caution if you have glaucoma or increased eye pressure.

Hyperglycemia
Hyperglycemia

This medicine may increase blood sugar.

Immunosuppression / infection risk
Immunosuppression / infection risk

This medicine may increase the risk of infections.

Breastfeeding warning
Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning
Pregnancy warning

Use during pregnancy only on medical advice.

Cardiac risk / QT prolongation / arrhythmias
Cardiac risk / QT prolongation / arrhythmias

This medicine may increase the risk of heart rhythm disturbances.

Salmeterol+fluticasone is a combination medication used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta-2 adrenergic agonist that relaxes airway muscles and improves airflow. Fluticasone is an inhaled corticosteroid that reduces inflammation and prevents exacerbations.

This combination is administered via inhalation, usually twice daily, and is indicated for patients requiring both bronchodilation and anti-inflammatory control. It is effective in reducing symptoms, preventing asthma attacks, and improving quality of life.

Common side effects include throat irritation, hoarseness, oral fungal infections (candidiasis), and tremors. In rare cases, severe adverse reactions such as paradoxical bronchospasm or adrenal suppression may occur. Patients are advised to rinse their mouth after use to reduce the risk of candidiasis.

Salmeterol+fluticasone is a valuable therapeutic option for patients with chronic respiratory conditions, providing effective symptom control and prevention of exacerbations.

General data about SERROFLO 25mcg / 125mcg / dose

  • Substance: salmeterol + fluticasone
  • Date of last drug list: 01-06-2026
  • Commercial code: W65229001
  • Concentration: 25mcg / 125mcg / dose
  • Pharmaceutical form: pressurized inhalation suspension
  • Quantity: 1
  • Product type: generic
  • Price: 102.09 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: S&D PHARMA CZ, SPOL.S.R.O - REPUBLICA CEHA
  • Holder: AMRING FARMA S.R.L. - ROMANIA
  • Number: 13290/2020/01
  • Shelf life: 2 years

Concentrations available for salmeterol + fluticasone

  • 25mcg/125mcg
  • 25mcg/125mcg/dose
  • 25mcg/250mcg
  • 25mcg/250mcg/dose
  • 25mcg/50mcg
  • 25mcg/50mcg/dose
  • 50mcg/100mcg
  • 50mcg/250mcg
  • 50mcg/250mcg/dose
  • 50mcg/500mcg
  • 50mcg/500mcg/dose
  • 50mg/100mg
  • 50mg/250mg
  • 50mg/500mg

Compensation lists for SERROFLO 25mcg / 125mcg / dose Amring Farma

B - Sublist B with 50% discount from the reference price

Price

Copayment

Patient

102.09 RON

31.17 RON

70.92 RON